NBIX

Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit. Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage addition

IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues

Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy

General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain.

Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare

Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia. Issues related to the Research and Development (R

IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues

Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy

Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare

Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy